Business
Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressingAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressingAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences throughout the course of 2020KZR-261, a first-in-class protein secretion inhibitor, is currently undergoing IND-enabling activities towards filing in Q1 2021 SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its fourth quarter and year end 2019 financial results and corporate highlights.\n “2019 marked several key milestones for Kezar, and I’m grateful for our team’s skill and hard work moving both of our programs forward. Our selective immunoproteasome inhibitor, KZR-616, entered Phase 2 trials in five different autoimmune diseases of high unmet need, building upon encouraging data from our ongoing Phase 1b study. We also nominated KZR-261, the first clinical candidate from our protein secretion program, and expect an IND filing in early 2021”, said John Fowler, Chief Executive Officer. “This year we look forward to sharing updates from the Phase 1b portion of our MISSION study, as well as an interim analysis from our MARINA trial in AIHA and ITP. Finally, after our successful financing last month, we have a strong cash position that takes us beyond all of our KZR-616 Phase 2 readouts as well as data with KZR-261 in multiple tumor types.” Recent Clinical and Business Highlights KZR-616 – Selective Immunoproteasome Inhibitor MISSION Study The Phase 1b/2 MISSION study in systemic lupus erythematosus (SLE) patients with and without nephritis is currently ongoing. Additional data from the Phase 1b portion of MISSION will be presented during various medical conferences throughout the course of 2020. The Phase 2 portion of MISSION is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of KZR-616 in patients with active proliferative lupus nephritis. The primary endpoints of this portion of the MISSION trial are safety and tolerability. Secondary and exploratory endpoints include pharmacokinetics (PK), pharmacodynamics (PD), biomarker assessments and additional measures of efficacy. This trial includes fou...